News

With admiration and gratitude, the ALS Society of Canada (ALS Canada) acknowledges the incredible contribution of our Board member, Dr. Christine Vande Velde, whose term has come to an end.     Dr. Vande Velde leaves her position on the Board…

The ALS Society of Canada (ALS Canada) is pleased to welcome Dr. Chantelle F. Sephton from Quebec and Craig Storey from Prince Edward Island to our Board of Directors. ALS Canada’s Board of Directors is comprised of volunteers from diverse…

Today the ALS Society of Canada (ALS Canada) recognizes the start of ALS Awareness Month across the country. Join us as we raise awareness for amyotrophic lateral sclerosis (ALS), a devastating disease that affects nearly 4,000 Canadians currently diagnosed and…

Celebrating ALS community member Kevin Daly, a new bursary of $2,500 supports the financial needs of post-secondary students Toronto, ON – In partnership with the friends and colleagues of ALS community member Kevin Daly, the ALS Society of Canada (ALS Canada) is pleased…

On April 25, 2023, the U.S. Food and Drug Administration (FDA) approved Qalsody (tofersen) for the treatment of SOD1-ALS under the Accelerated Approval pathway. On May 30, 2024, the European Commission (EC) has granted marketing authorization for Qalsody (tofersen) under…

ALS researchers from around the world continue to build upon existing work and make new discoveries in the hopes of realizing a future without ALS. In the March 2023 Research Update, you’ll learn about the progress researchers have made in…

Nine projects to advance the ALS research landscape funded through ALS Society of Canada and Brain Canada partnership, with support from the Dr. Jean-Pierre Canuel Fund – SLA Québec. Toronto – The ALS Society of Canada (ALS Canada) and Brain…

Today, the Federal Government announced the National Strategy for Drugs for Rare Diseases. We are pleased to see this strategy move forward and hope it will be a significant step in building knowledge and improving access to therapies for people…